obesity drug news today glp-1 oct 27 2025 KFF's survey of Medicaid officials found 16 state Medicaid programs covered GLP-1s for treatment as of October 2025. Since then, four states (CA, NH, PA, SC) have ended coverage and NC 🔬 GLP-1/GIP Therapy Discontinuation: YGroup_MetabolismIgnite Bottle Quantity:GLP-1 Boost - 3 Bottles - 30% OFF

obesity drug news today glp-1 oct 27 2025 KFF's survey of Medicaid officials found 16 state Medicaid programs covered GLP-1s for treatment as of October 2025. Since then, four states (CA, NH, PA, SC) have ended coverage and NC 🔬 GLP-1/GIP Therapy Discontinuation: YGroup_MetabolismIgnite Bottle Quantity:GLP-1 Boost - 3 Bottles - 30% OFF

🔬 GLP-1/GIP Therapy Discontinuation: Why the “How” Matters One of the most-discussed challenges with GLP-1/GIP agonists such as tirzepatide (Mounjaro®) is weight regain after stopping therapy. What… | Paramesh Shamanna | 10

While there might be concerns about weight regain after stopping GLP-1 medications, microdosing offers benefits like improved mood and focus

YGroup_MetabolismIgnite

Bottle Quantity:GLP-1 Boost - 3 Bottles - 30% OFF

Your provider will evaluate BMI (≥27 with comorbidities or ≥30), metabolic status, medication interactions, and contraindications